Current stock page

Financial Data

TRVI Financial Data

Revenue · Earnings · Margins · Balance Sheet · Cash Flow

HealthcareBiotechnologyScore data as of Nov 13, 2026

TRVITrevi Therapeutics, Inc.

Healthcare / Biotechnology

Relative Leader / Watch

Sector Leader

NeutralEdge 10/10
$13.65+$0.03 (+0.22%)

Latest quote

  • Momentum
    52
  • Value
    —
  • Quality
    82
  • Risk resilience
    51
  • Sentiment
    —
algovestiq.comScore data as of Nov 13, 2026

Financial Data Overview

Detailed revenue, earnings, margins, balance sheet, cash flow, valuation metrics, technical indicators, and risk measures for deeper research.

Quarterly periods
8
Fundamental metrics
10
Technical indicators
12
Risk measures
6

Quarterly Financial Statements

Updated Nov 16, 2026.

Income statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Revenue$0$0$0$0$0$0$0$0
Gross Profit$0$0-$34K$0$0$0$0-$38K
Operating Income-$24.49M-$20.51M-$14.91M-$10.22M-$13.92M-$13.72M-$11.47M-$12.24M
Net Income-$21.45M-$17.8M-$13.19M-$8.32M-$11.8M-$12.3M-$10.34M-$11.42M
EPS-$0.13-$0.11-$0.09-$0.06-$0.08-$0.09-$0.09-$0.11
Cash flow statement
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Operating Cash Flow-$19.69M-$17.43M-$16.69M-$7.63M-$10.88M-$10.1M-$13.48M-$9.55M
Capital Expenditure-$25K-$124K-$102K$0-$12K$0$0-$7K
Free Cash Flow-$19.71M-$17.55M-$16.79M-$7.63M-$10.89M-$10.1M-$13.48M-$9.56M
Net Cash Provided By Operating Activities-$19.69M-$17.43M-$16.69M-$7.63M-$10.88M-$10.1M-$13.48M-$9.55M
Balance sheet
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
Total Assets$310.81M$330.52M$179.61M$193.44M$199.36M$208.34M$107M$110.9M
Total Debt$527K$605K$682K$753K$823K$891K$957K$1.03M
Cash And Cash Equivalents$27.85M$54.3M$19.41M$18.91M$56.87M$117.06M$19.37M$34.1M
Total Liabilities$8.06M$9.01M$7.48M$10.2M$9.57M$9.85M$7.55M$11.26M
Total Stockholders Equity$302.76M$321.51M$172.13M$183.24M$189.79M$198.49M$99.46M$99.64M
Key financial metrics
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.089.0112.48.898.764.797.86.98
P/S ratio————————
Debt To Equity0000000.010.01
Free Cash Flow Yield-1.97%-1.36%-1.50%-1.76%-2.65%-4.49%-5.32%-5.51%
Financial ratios
8 periods
Metric2026-09-302026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-31
P/E ratio————————
P/B ratio8.089.0112.48.898.764.797.86.98
P/S ratio————————
Return On Equity-20.07%-15.90%-26.50%-23.33%-24.16%-23.83%-47.61%-48.08%
Debt To Equity0000000.010.01

Current Stock Metrics

Current fundamental, technical, and risk readings in one place.

Fundamental metrics
MetricValue
Pe-35.2x
Pb7.2x
EPS Growth Yoy-62.50%
Gross Margin0.00%
Operating Margin0.00%
ROE-24.81%
ROIC-23.09%
Debt To Equity0
FCF Yield-3.17%

As of Nov 13, 2026

Technical indicators
MetricValue
Close$13.65
Volume1.1M
RSI (14)48.45
MACD0.13
MACD signal0
MACD histogram0.12
ADX (14)22.74
SMA (50)$14.03
SMA (200)$14.52
ATR (14)$0.91
Historical volatility (annualized)76.93%
Volume (20-day average)1.62M

As of Nov 13, 2026

Risk measures
MetricValue
Resilience score51/100
Beta1.38
Annual volatility59.27%
Max Drawdown-39.08%
Sharpe Ratio0.52
VaR (95%, 1-day)-5.39%

As of Nov 13, 2026

Detailed Metrics

Additional measures remain available here while the decision pages stay focused.

Additional fundamental metrics

No additional fundamental metrics are available.

Additional technical indicators

No additional technical indicators are available.

Additional risk measures

No additional risk measures are available.

TRVI Financial Data FAQ

What is Trevi Therapeutics, Inc.'s revenue?

Trevi Therapeutics, Inc.'s revenue is one of the core financial data points for TRVI. Use it with revenue growth, margins, and EPS to understand whether sales are translating into earnings power.

Is Trevi Therapeutics, Inc.'s revenue growing?

Revenue growth shows whether Trevi Therapeutics, Inc. is expanding from prior periods. Compare growth with margins and free cash flow because faster sales growth is more valuable when profitability holds up.

What is TRVI's EPS?

TRVI's EPS, or earnings per share, helps connect net income to each share. EPS should be compared with EPS growth, P/E ratio, and analyst expectations.

What is Trevi Therapeutics, Inc.'s net income?

Trevi Therapeutics, Inc.'s net income shows profit after costs, taxes, and other expenses. It should be read with revenue, operating margin, EPS, and free cash flow.

How much free cash flow does Trevi Therapeutics, Inc. generate?

Free cash flow shows how much cash Trevi Therapeutics, Inc. generates after capital spending. It is useful for judging reinvestment capacity, buybacks, debt reduction, and valuation support.

How much cash and debt does Trevi Therapeutics, Inc. have?

Cash and debt help frame TRVI's balance-sheet flexibility. Compare liquidity and leverage with free cash flow and profitability before judging financial strength.